X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
The Company plans to use the proceeds to further the Phase II Non-Muscle Invasive Bladder Cancer (NMIBC), evaluating Ruvidar (TLD-1433), a ruthenium-based photodynamic compound.
Lead Product(s): TLD-1433
Therapeutic Area: Oncology Product Name: Ruvidar
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $0.5 million Upfront Cash: Undisclosed
Deal Type: Private Placement April 24, 2024
Details:
The net proceeds will be used for the development of Ruvidar (TLD-1433), a novel photosensitizer, currently being evaluated in a phase II clinical trial for treating high-risk non-muscle invasive bladder cancer.
Lead Product(s): TLD-1433
Therapeutic Area: Oncology Product Name: Ruvidar
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: TSX Venture Exchange
Deal Size: $0.8 million Upfront Cash: Undisclosed
Deal Type: Private Placement February 05, 2024
Details:
TLD-1433 (ruvidar) is a ruthenium-based photodynamic compound. It is under phase 2 clinical development for the treatment of patients with non-muscle invasive bladder cancer.
Lead Product(s): TLD-1433
Therapeutic Area: Oncology Product Name: Ruvidar
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 15, 2024
Details:
The Company plans to use the proceeds to further the Phase II Non-Muscle Invasive Bladder Cancer (NMIBC) clinical study evaluating Ruvidar (TLD-1433), a light-activated compound.
Lead Product(s): TLD-1433,Photodynamic Therapy
Therapeutic Area: Oncology Product Name: Ruvidar
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Research Capital Corporation
Deal Size: $0.8 million Upfront Cash: Undisclosed
Deal Type: Private Placement November 29, 2023
Details:
The Company plans to use the proceeds to further the Phase II Non-Muscle Invasive Bladder Cancer (NMIBC) clinical study evaluating Ruvidar (TLD-1433), a light-activated compound.
Lead Product(s): TLD-1433,Photodynamic Therapy
Therapeutic Area: Oncology Product Name: Ruvidar
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Research Capital Corporation
Deal Size: $1.1 million Upfront Cash: Undisclosed
Deal Type: Private Placement November 17, 2023
Details:
The Company plans to use the proceeds to further the Phase II Non-Muscle Invasive Bladder Cancer (NMIBC) clinical study evaluating Ruvidar (TLD-1433), a light-activated compound.
Lead Product(s): TLD-1433
Therapeutic Area: Oncology Product Name: Ruvidar
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Research Capital Corporation
Deal Size: $2.6 million Upfront Cash: Undisclosed
Deal Type: Financing October 23, 2023
Details:
TLD-1433 on activation by radiation therapy has been demonstrated to be effective in the destruction of human GBM cancer cells. Currently being investigated for non-muscle invasive bladder cancer.
Lead Product(s): TLD-1433
Therapeutic Area: Oncology Product Name: TLD-1433
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 23, 2023
Details:
Ruvidar (TLD-1433), is an exciting new drug candidate for the treatment for NMIBC and has been proven to be safe and effective in a phase Ib clinical study in the safe and effective treatment of NMIBC.
Lead Product(s): TLD-1433,Photodynamic Therapy
Therapeutic Area: Oncology Product Name: Ruvidar
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 16, 2023
Details:
The Company intends to use the proceeds for the advancement of Phase II non-muscle invasive bladder cancer clinical study evaluating TLD 1433, a ruthenium metal-based molecule.
Lead Product(s): TLD-1433
Therapeutic Area: Oncology Product Name: Ruvidar
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $0.9 million Upfront Cash: Undisclosed
Deal Type: Private Placement June 30, 2023
Details:
TLD-1433 on activation by radiation therapy has been demonstrated to be effective in the destruction of human GBM cancer cells. Currently being investigated for non-muscle invasive bladder cancer.
Lead Product(s): TLD-1433
Therapeutic Area: Oncology Product Name: TLD-1433
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 02, 2023
Details:
TLD-1433 is a patented PDC with 12 years of published peer reviewed preclinical research and is currently under investigation in Study II. Study II utilizes the therapeutic dose of TLD-1433 (0.70 mg/cm2) activated by the proprietary TLC-3200 medical laser system.
Lead Product(s): TLD-1433
Therapeutic Area: Oncology Product Name: TLD-1433
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 25, 2023
Details:
Company intends to use the proceeds for the IV installation of Rutherrin (TLD-1433) intended for the treatment of non small lung cancer and glio blastoma multiforme, advancement of phase II non-muscle invasive bladder cancer clinical study and for general corporate purposes.
Lead Product(s): TLD-1433
Therapeutic Area: Oncology Product Name: TLD-1433
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: TSX Venture Exchange
Deal Size: $0.2 million Upfront Cash: Undisclosed
Deal Type: Private Placement November 17, 2022
Details:
The company intends to use the proceeds for the GLP toxicology study for intravenous installation of Rutherrin intended for the treatment of Non Small Lung Cancer and Glioblastoma Multiforme and advancement of TLD-1433 phase 2 Non-Muscle Invasive Bladder Cancer clinical study.
Lead Product(s): TLD-1433
Therapeutic Area: Oncology Product Name: TLD-1433
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Research Capital Corporation
Deal Size: $1.8 million Upfront Cash: Undisclosed
Deal Type: Private Placement October 03, 2022
Details:
The company intends to use the proceeds for the GLP toxicology study for intravenous installation of Rutherrin intended for the treatment of Non Small Lung Cancer and Glioblastoma Multiforme and advancement of TLD-1433 phase 2 Non-Muscle Invasive Bladder Cancer clinical study.
Lead Product(s): TLD-1433
Therapeutic Area: Oncology Product Name: TLD-1433
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $2.5 million Upfront Cash: Undisclosed
Deal Type: Private Placement September 22, 2022
Details:
TLD-1433 is a patented PDC with over 10 years of published peer-reviewed preclinical and clinical research and is currently under investigation in Study II.
Lead Product(s): TLD-1433
Therapeutic Area: Oncology Product Name: TLD-1433
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 21, 2022
Details:
For 38 patients enrolled and treated in Study II for TLD-1433, which is a patented Photodynamic Compound, 44.7% achieved CR at 90 days, with 50% achieving CR with evaluable patients and potential of 71.1% if all PR and pending patients achieved CR.
Lead Product(s): TLD-1433
Therapeutic Area: Oncology Product Name: TLD-1433
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 05, 2022
Details:
The primary purpose of Study II is to discover if the TLD-1433 combined with TLC-3200 (“Study Device”) are effective in the destruction of Bacillus Calmette-Guérin Unresponsive Non-Muscle Invasive Bladder Cancer.
Lead Product(s): TLD-1433
Therapeutic Area: Oncology Product Name: TLD-1433
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 30, 2020
Details:
Study II utilizes the Therapeutic Dose of the Study Drug (TLD-1433, Theralase's patented PDC), in conjunction with the Study Device (TLC-3200 Medical Laser System) intended to deliver a safe and effective treatment to patients inflicted with BCG-Unresponsive NMIBC.
Lead Product(s): TLD-1433
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 19, 2020
Details:
Enrollment of new patients and conducting the first treatment procedure in the Company's Phase II Non-Muscle Invasive Bladder Cancer clinical study has been temporarily placed on hold.
Lead Product(s): TLD-1433
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 20, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
